276 related articles for article (PubMed ID: 33217946)
1. Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors.
Voynov V; Adam PJ; Nixon AE; Scheer JM
Antibodies (Basel); 2020 Nov; 9(4):. PubMed ID: 33217946
[TBL] [Abstract][Full Text] [Related]
2. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
Baeuerle PA; Wesche H
Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
[TBL] [Abstract][Full Text] [Related]
3. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.
Yoneyama T; Kim MS; Piatkov K; Wang H; Zhu AZX
PLoS Comput Biol; 2022 Jul; 18(7):e1009715. PubMed ID: 35839267
[TBL] [Abstract][Full Text] [Related]
4. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.
Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743
[TBL] [Abstract][Full Text] [Related]
6. T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy.
Li Y; Zhao W; Shen Y; Xu Y; Chen S; Pan L
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672132
[TBL] [Abstract][Full Text] [Related]
7. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
8. Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors.
Mortezaee K; Majidpoor J
Biomed Pharmacother; 2023 Jun; 162():114621. PubMed ID: 37004328
[TBL] [Abstract][Full Text] [Related]
9. A Mechanistic Physiologically-Based Pharmacokinetic Platform Model to Guide Adult and Pediatric Intravenous and Subcutaneous Dosing for Bispecific T Cell Engagers.
Zhang X; Lumen A; Wong H; Connarn J; Dutta S; Upreti VV
Clin Pharmacol Ther; 2024 Mar; 115(3):457-467. PubMed ID: 37746860
[TBL] [Abstract][Full Text] [Related]
10. Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.
Strohl WR; Naso M
Antibodies (Basel); 2019 Jul; 8(3):. PubMed ID: 31544847
[TBL] [Abstract][Full Text] [Related]
11. Strategies for clinical dose optimization of T cell-engaging therapies in oncology.
Ball K; Dovedi SJ; Vajjah P; Phipps A
MAbs; 2023; 15(1):2181016. PubMed ID: 36823042
[TBL] [Abstract][Full Text] [Related]
12. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
13. Bispecific T-cell engagers for treatment of multiple myeloma.
Ravi G; Costa LJ
Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
[TBL] [Abstract][Full Text] [Related]
14. T-cell-engaging Therapy for Solid Tumors.
de Miguel M; Umana P; Gomes de Morais AL; Moreno V; Calvo E
Clin Cancer Res; 2021 Mar; 27(6):1595-1603. PubMed ID: 33082210
[TBL] [Abstract][Full Text] [Related]
15. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Friedrich MJ; Neri P; Kehl N; Michel J; Steiger S; Kilian M; Leblay N; Maity R; Sankowski R; Lee H; Barakat E; Ahn S; Weinhold N; Rippe K; Bunse L; Platten M; Goldschmidt H; Müller-Tidow C; Raab MS; Bahlis NJ
Cancer Cell; 2023 Apr; 41(4):711-725.e6. PubMed ID: 36898378
[TBL] [Abstract][Full Text] [Related]
16. Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy.
Kobold S; Pantelyushin S; Rataj F; Vom Berg J
Front Oncol; 2018; 8():285. PubMed ID: 30090763
[TBL] [Abstract][Full Text] [Related]
17. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
18. Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Sam J; Colombetti S; Fauti T; Roller A; Biehl M; Fahrni L; Nicolini V; Perro M; Nayak T; Bommer E; Schoenle A; Karagianni M; Le Clech M; Steinhoff N; Klein C; Umaña P; Bacac M
Front Oncol; 2020; 10():575737. PubMed ID: 33330050
[TBL] [Abstract][Full Text] [Related]
19. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
20. Perspective: Designing T-Cell Engagers With Better Therapeutic Windows.
Vafa O; Trinklein ND
Front Oncol; 2020; 10():446. PubMed ID: 32351885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
